SCHEMBL4285263

SCHEMBL4285263

Cn1c(=O)c(-c2ccc(F)c(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c2)cc2cnc(N)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.47
PDGFRB P09619 2/20 0.47
SRC P12931 2/20 0.45
EGFR P00533 1/20 0.45
FGFR1 P11362 1/20 0.45
FGFR2 P21802 1/20 0.45
FGFR4 P22455 1/20 0.45
FGFR3 P22607 1/20 0.45
TRPV1 Q8NER1 7/20 0.45
RIPK1 Q13546 2/20 0.44
BRAF P15056 2/20 0.44
FLT3 P36888 2/20 0.44
ABL1 P00519 1/20 0.44
LCK P06239 1/20 0.44
CSF1R P07333 1/20 0.44
LYN P07948 1/20 0.44
KIT P10721 1/20 0.44
FLT1 P17948 1/20 0.44
FLT4 P35916 1/20 0.44
BLK P51451 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4553219 0.90 KDR (0.51) KDRPDGFRBSRCEGFRFGFR1
SCHEMBL5057707 0.89 KDR (0.44) KDRPDGFRBSRCTRPV1BRAF
SCHEMBL5062417 0.86 LCK (0.55) KDRPDGFRBSRCEGFRFGFR1
SCHEMBL4276354 0.83 KDR (0.47) KDRPDGFRBSRCEGFRFGFR1
SCHEMBL4552750 0.82 FGFR1 (0.48) KDRPDGFRBSRCEGFRFGFR1
SCHEMBL4551949 0.81 BRAF (0.49) KDRPDGFRBSRCEGFRFGFR1
SCHEMBL5062436 0.80 KDR (0.48) KDRPDGFRBFGFR1TRPV1BRAF
SCHEMBL5065297 0.80 FGFR1 (0.48) KDRSRCEGFRFGFR1FGFR2
SCHEMBL4551503 0.79 BRAF (0.65) KDRPDGFRBSRCEGFRFGFR1
SCHEMBL5065431 0.78 BRAF (0.46) KDRSRCEGFRFGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP claimed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO claimed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 KDR 500/4885PDGFRB 2165/4885SRC 417/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KDR 500/4885PDGFRB 2165/4885SRC 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.